Journal Menu
► ▼ Journal Menu-
- Vaccines Home
- Aims & Scope
- Editorial Board
- Reviewer Board
- Topical Advisory Panel
- Early Career Editorial Board
- Instructions for Authors
- Special Issues
- Topics
- Sections & Collections
- Article Processing Charge
- Indexing & Archiving
- Editor’s Choice Articles
- Most Cited & Viewed
- Journal Statistics
- Journal History
- Journal Awards
- Conferences
- Editorial Office
Journal Browser
► ▼ Journal BrowserNeed Help?
Announcements
29 January 2026
Vaccines | Highly Cited Papers in the First Half of 2025
by Ankita Saha, Sounak Ghosh Roy, Richa Dwivedi, Prajna Tripathi, Kamal Kumar, Shashank Manohar Nambiar and Rajiv Pathak
Vaccines 2025, 13(4), 424; https://doi.org/10.3390/vaccines13040424
Available online: https://www.mdpi.com/2076-393X/13/4/424
2. “Advances and Challenges in Aeromonas hydrophila Vaccine Development: Immunological Insights and Future Perspectives”
by Kavi R. Miryala and Banikalyan Swain
Vaccines 2025, 13(2), 202; https://doi.org/10.3390/vaccines13020202
Available online: https://www.mdpi.com/2076-393X/13/2/202
3. “Molecular Farming for Immunization: Current Advances and Future Prospects in Plant-Produced Vaccines”
by Dang-Khoa Vo and Kieu The Loan Trinh
Vaccines 2025, 13(2), 191; https://doi.org/10.3390/vaccines13020191
Available online: https://www.mdpi.com/2076-393X/13/2/191
4. “Revolutionizing Nanovaccines: A New Era of Immunization”
by Mohammed Saleh, Ahmed El-Moghazy, Adel H. Elgohary, WesamEldin I. A. Saber and Yosra A. Helmy
Vaccines 2025, 13(2), 126; https://doi.org/10.3390/vaccines13020126
Available online: https://www.mdpi.com/2076-393X/13/2/126
5. “Pediatric Vaccine Hesitancy in the United States—The Growing Problem and Strategies for Management Including Motivational Interviewing”
by Ashlesha Kaushik, Julia Fomicheva, Nathan Boonstra, Elizabeth Faber, Sandeep Gupta and Helen Kest
Vaccines 2025, 13(2), 115; https://doi.org/10.3390/vaccines13020115
Available online: https://www.mdpi.com/2076-393X/13/2/115
6. “Progress and Challenges in HIV-1 Vaccine Research: A Comprehensive Overview”
by Alex C. Boomgarden and Chitra Upadhyay
Vaccines 2025, 13(2), 148; https://doi.org/10.3390/vaccines13020148
Available online: https://www.mdpi.com/2076-393X/13/2/148
7. “Pertussis in Early Infancy: Diagnostic Challenges, Disease Burden, and Public Health Implications Amidst the 2024 Resurgence, with Emphasis on Maternal Vaccination Strategies”
by Konstantina Leontari, Alexandra Lianou, Andreas G. Tsantes, Filippos Filippatos, Zoi Iliodromiti, Theodora Boutsikou, Styliani Paliatsou, Anastasios E. Chaldoupis, Petros Ioannou, Alexandra Mpakosi et al.
Vaccines 2025, 13(3), 276; https://doi.org/10.3390/vaccines13030276
Available online: https://www.mdpi.com/2076-393X/13/3/276
8. “No Increased Risk of Autoimmune Diseases Following HPV Vaccination: A Systematic Review and Meta-Analysis”
by Filippo Alberto Ferrari, Enrico Ciminello, Marcello Ceccaroni, Matteo Pavone, Violante Di Donato, Giorgia Perniola, Pierluigi Benedetti Panici, Ludovico Muzii, Andrea Giannini, Giuseppe Vizzielli et al.
Vaccines 2025, 13(4), 391; https://doi.org/10.3390/vaccines13040391
Available online: https://www.mdpi.com/2076-393X/13/4/391
9. “The New Era of Pneumococcal Vaccination in Adults: What Is Next?”
by Lale Ozisik
Vaccines 2025, 13(5), 498; https://doi.org/10.3390/vaccines13050498
Available online: https://www.mdpi.com/2076-393X/13/5/498
10. “Advancing Breast Cancer Treatment: The Role of Immunotherapy and Cancer Vaccines in Overcoming Therapeutic Challenges”
by Marco Palma
Vaccines 2025, 13(4), 344; https://doi.org/10.3390/vaccines13040344
Available online: https://www.mdpi.com/2076-393X/13/4/344
11. “Dengue Vaccination: A Practical Guide for Clinicians”
by Kay Choong See
Vaccines 2025, 13(2), 145; https://doi.org/10.3390/vaccines13020145
Available online: https://www.mdpi.com/2076-393X/13/2/145
12. “Human Endogenous Retroviruses as Novel Therapeutic Targets in Neurodegenerative Disorders”
by Elena Rita Simula, Seyedesomaye Jasemi, Davide Cossu, Milena Fais, Ilaria Cossu, Vanna Chessa, Mattia Canu and Leonardo Antonio Sechi
Vaccines 2025, 13(4), 415; https://doi.org/10.3390/vaccines13040415
Available online: https://www.mdpi.com/2076-393X/13/4/415
13. “Past, Present, and Future of Viral Vector Vaccine Platforms: A Comprehensive Review”
by Justin Tang, Md Al Amin and Jian L. Campian
Vaccines 2025, 13(5), 524; https://doi.org/10.3390/vaccines13050524
Available online: https://www.mdpi.com/2076-393X/13/5/524
14. “Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical Therapies”
by Sahar Balkhi, Giorgia Bilato, Andrea De Lerma Barbaro, Paola Orecchia, Alessandro Poggi and Lorenzo Mortara
Vaccines 2025, 13(1), 69; https://doi.org/10.3390/vaccines13010069
Available online: https://www.mdpi.com/2076-393X/13/1/69
15. “Maternal Immunization: Current Evidence, Progress, and Challenges”
by Veronica Santilli, Mayla Sgrulletti, Giorgio Costagliola, Alessandra Beni, Maria Felicia Mastrototaro, Davide Montin, Caterina Rizzo, Baldassarre Martire, Michele Miraglia del Giudice and Viviana Moschese on behalf of the Italian Society of Pediatric Allergy and Immunology (SIAIP) Vaccine Committee
Vaccines 2025, 13(5), 450; https://doi.org/10.3390/vaccines13050450
Available online: https://www.mdpi.com/2076-393X/13/5/450
20 January 2026
Meet Us at the 10th Asia Pacific Region Conference of the International Union Against Tuberculosis and Lung Disease (APRC 2026), 4–7 February 2026, Bangkok, Thailand
MDPI will be attending the 10th Asia Pacific Region Conference of the International Union Against Tuberculosis and Lung Disease (APRC 2026) from 4 to 7 February 2026 in Bangkok, Thailand. With over 1,000 experts and delegates expected from across the Asia-Pacific region and beyond, APRC 2026 will provide a dynamic platform for collaboration, knowledge exchange, and actionable solutions that shape the future of lung health worldwide.
The theme of APRC 2026 is “Transforming Lung Health and Creating a Future Free of Tuberculosis through Research, Innovation, and Networking”. The conference will cover the following:
- Tuberculosis research and treatment innovations;
- Emerging respiratory infectious diseases;
- Universal health coverage and access to care;
- Environmental and societal impacts on lung health;
- Breakthroughs in non-communicable respiratory diseases, including asthma, COPD, lung cancer, and interstitial lung disease.
The following open access journals will be represented at the conference:
We invite you to visit MDPI’s booth (#A45) to meet our representatives, explore our latest initiatives, and discuss potential collaborations. For more details about the conference, please visit the official website: https://aprc2026.org/.
We look forward to connecting with you in Bangkok!
9 January 2026
MDPI’s Newly Launched Journals in December 2025
We have expanded our open access portfolio with eight new journals publishing their inaugural issues in December 2025, as well as three journal transfers. These additions span physical sciences, social sciences, arts and humanities, environmental and Earth sciences, medicine and pharmacology, and public health and healthcare. We extend our sincere thanks to the Editors-in-Chief, Associate Editors, and Editorial Board Members who are shaping these journals’ direction. All journals uphold strong editorial standards through a thorough peer review process, ensuring impactful open access scholarship.
Please feel free to browse and discover more about the new journals below.
|
New Journals |
Founding Editor-in-Chief(s) |
Journal Topics (Selected) |
|
|
Dr. Elisa Felicitas Arias, Université PSL, France |
atomic clocks; time and frequency metrology; GNSS systems; relativity and relativistic timekeeping; fundamental physics in space | |
|
|
Prof. Dr. José F.F. Mendes, University of Aveiro, Portugal |
complex systems; network science; nonlinear dynamics and chaotic behaviour; information theory and complexity; computational complexity | |
|
|
Prof. Dr. Roberto Morandotti, Institut National de la Recherche Scientifique—Énergie, Matériaux et Télécommunications (INRS), Canada |
light generation; light sources and applications; light control and measurement; human responses to light; lighting design | |
|
|
Prof. Dr. Savvas A. Chatzichristofis, Neapolis University Pafos, Cyprus |
generative AI and large language models in education; multimodal and embodied AI; personalization and adaptive systems; assessment, feedback, and academic integrity; learning analytics | |
|
|
Prof. Dr. Jon Andoni Duñabeitia, Universidad Nebrija, Spain |
cognitive psychology; cognitive neuroscience; psycholinguistics; applied linguistics; experimental psychology | |
|
|
Prof. Dr. Caiwu Fu, Wuhan University, China; Prof. Dr. Longxi Zhang, Peking University, China |
cultural practices; cultural theory; cultural policy; cultural heritage; transregional and transnational cultural flows| |
|
|
Dr. Ghassem R. Asrar, iCREST Environmental Education Foundation, USA |
biosphere interactions, processes, and sustainability; ecosystem science and dynamics; biodiversity conservation; global change and environmental adaptation; biogeochemical cycles | |
|
|
Dr. Giuseppe Mulè, University of Palermo, Italy |
cardiorenal syndromes; chronic heart failure and chronic kidney disease; cardiorenalmetabolic syndrome; hypertension and diabetes in relation to the abovementioned syndromes; diagnostic techniques | |
|
Transferred Journals |
Editor-in-Chief |
Journal Topics (Selected) |
|
|
Prof. Dr. Peter Matt, Lucerne Cantonal Hospital (LUKS), Switzerland |
cardiology; cardiovascular and aortic surgery; cardiovascular anatomy, physiology and pathophysiology; congenital heart disease and pediatric cardiology; cardiovascular regenerative and reparative medicine | |
|
|
Prof. Dr. Oana Săndulescu, Carol Davila University of Medicine and Pharmacy, Romania; National Institute for Infectious Diseases “Prof. Dr. Matei Bals”, Romania |
infectious diseases across clinical and public health domains; epidemiology of communicable diseases; clinical microbiology and applied virology; vaccinology and immunization; host–pathogen interactions and immunity | |
|
|
Dr. Roxana Elena Bohiltea, “Carol Davila” University of Medicine and Pharmacy, Romania |
public health; disease prevention; screening and early detection; lifestyle interventions and health education; digital and innovative prevention | |
We would like to thank everyone who has supported the development of open access publishing. If you would like to create more new journals, you are welcome to send an application here, or contact the New Journal Committee (newjournal-committee@mdpi.com).
31 December 2025
MDPI INSIGHTS: The CEO's Letter #30 - Scaling with Integrity, Highly Cited Researchers, KEMÖ Consortium, Michele Parrinello, and Best PhD Thesis Awards
Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts

With colleagues at MDPI headquarters in Basel, representing the people behind our global growth and shared commitment to integrity.
Scaling with Integrity: A Year of Growth, Responsibility, and Trust
When I look back on 2025, one phrase seems to sum up the year: “Scaling with integrity.” That was our watchword for 2025, and it will remain so as we move forward in to 2026.
Our journal portfolio continued to grow in 2025, reflecting the trust of a widening proportion of the scholarly community.
Today, MDPI has 355 journals indexed in Scopus and 330 in Web of Science – a testimonial to the scale at which our journals meet established external quality criteria. During the year, 45 of our journals were newly accepted into Scopus and 29 into Web of Science (this excludes transferred journals to our portfolio that were already indexed), following rigorous, independent evaluation by the world’s leading indexing bodies
Meeting external quality benchmarks
These results underline the fact that scaling responsibly is not only about expanding our catalogue, but also about meeting external quality benchmarks consistently, transparently, and at scale. Our indexing performance remains one of the strongest independent validations of MDPI’s commitment to rigor, trust, and long-term sustainability.
Over the course of 2025, we made targeted investments to ensure that the integrity of our editorial process scaled to keep pace with our growth. We strengthened our editorial governance by doubling down on our dedicated Publication Ethics department, appointing a Head of Ethics, and expanding our research integrity team by the addition of new specialists plus the creation of embedded editorial ethics roles across key journals. We also introduced new internal ethics guidelines, pre-review integrity checks, and monitoring dashboards to help teams identify potential issues and apply consistent standards across our portfolio.
Besides investing in systems and tools, we of course also invested heavily in our people and culture, delivering organisation-wide training on topics such as image integrity, AI use in publishing, and ethical oversight, while actively engaging with the wider publishing community through COPE and STM forums.
All these efforts reflect a simple principle: growth only matters if it is matched by rigor, responsibility, and trust.
Technology and AI: Supporting the editorial decision-making process
At MDPI, AI is designed to assist, not replace, editorial decision-making. It is one element in a broader system that combines people, technology, and processes to support scale responsibly.
In 2025, we continued to invest heavily in technology that supports quality rather than shortcuts. Our AI team doubled in size, ensuring that increased automation goes hand-in-hand with expertise and oversight. Proprietary AI tools such as Scholar Finder have significantly improved the precision of reviewer matching, while Ethicality has been widely adopted across editorial workflows to identify contextual signals, such as scope alignment and citation behaviour, so that human judgment can be applied where it matters most.
Partnerships: Institutional Open Access Program (IOAP) agreements and Societies
Our recent growth is also reflected in the strength of our partnerships. In 2025, we entered into more than 150 new IOAP agreements, bringing our total to 975 active agreements worldwide. This activity included the signing of our first-ever consortium agreements in North America, renewals of all major national consortia in the UK, Switzerland, Sweden, Norway, Austria, and Croatia, and the conclusion of several flat-fee agreements. At the same time, we concluded a total of 30 agreements, encompassing 24 new Society affiliations, four strategic publishing partnerships, and two journal acquisitions.
In 2025, we opened MDPI USA in Philadelphia – our latest global office, which complements our Toronto office in representing North America. MDPI USA is responsible for accelerating Open Access in the US through ongoing support of our scholars and for expanding our institutional and society partnerships.
On the other side of the globe, meanwhile, we signed an IOAP agreement in India, allowing researchers discounted Article Processing Charges (APCs), streamlined APC management for universities, and visibility into submissions, supporting India’s push for wider Open Access by offering flexible models and helping institutions meet national mandates such as Plan S.
Sustainability, sponsorships and awards
We continued to expand our sustainability efforts during 2025, hosting the 11th World Sustainability Forum, awarding CHF 125,000 in sustainability-related funding, and launching the Z-Forum on Sustainability and Innovation conference, which will officially take place in January 2026.
We also saw a record year for conference sponsorships and awards (while establishing new awards such as the Michele Parrinello Award), recognising scholars across disciplines and reinforcing our commitment to supporting the global research community at every stage of the academic journey.
Deepening our relationships
In 2025, I had the opportunity to travel more widely than ever before on MDPI business, meeting many of our stakeholders face to face and relishing the opportunity to gain a deeper understanding of their science communication needs. It was also excellent to visit a large number of MDPI offices and witness the commitment and service orientation of so many of our colleagues around the world. I shall resume my itinerary in the new year, and I look forward to many more such interactions.
Looking ahead to 2026, we will be celebrating a very significant milestone: 30 years of MDPI. From our foundation as a single Open Access journal in 1996 to the global publishing organisation we are today, our mission has remained consistent: advancing Open Access through rigorous and trustworthy scientific communication.
I would like to take this opportunity to thank all our stakeholders – authors, Editors-in-Chief, Editorial Board members, and reviewers – who have placed their trust in us during 2025. On behalf of the entire MDPI team, I look forward to deepening our relationships yet further in 2026 and celebrating 30 Years of Open Science at MDPI, something we’ve built together.

Basel, Switzerland, where MDPI was founded in 1996.
Impactful Research

621 MDPI Editors Named Highly Cited Researchers in 2025
I am pleased to share an important milestone for our editorial community and for MDPI. In late November, Clarivate announced the 2025 Highly Cited Researchers, and 621 MDPI Editorial Board Members were included among the most influential scientific contributors over the past decade!
The 621 editors come from 33 countries, representing 21 scientific disciplines, and account for nearly one in every ten Highly Cited Researchers globally. This recognition speaks to the depth of expertise across our Editorial Boards and the strength of the scientific communities that choose to collaborate with MDPI. It is important to note that while citation metrics are not in themselves a proxy for quality, they do offer one lens on sustained scientific influence.
“Our strength comes from the scientific communities who choose to work with us”
Why this is important
Having more than 600 editors recognized on this list highlights:
- The high level of expertise guiding peer review across our journals
- The global and disciplinary diversity within our Editorial Boards
- Our commitment to maintaining strong, knowledgeable, and engaged editorial oversight
Impactful science is of course shaped by broad, diverse research communities, and no single metric captures the full picture of research quality. However, this recognition does serve as meaningful, independent affirmation of the calibre of many editors who contribute to MDPI’s work.
A closer look at the recognition
Clarivate’s methodology highlights researchers whose publications rank in the top one per cent by citation count, reflecting consistent influence over the past decade. The process includes:
- Evaluation of c. 200,000 highly cited papers
- Removal of retracted publications
- Filtering of papers with unusually large authorship groups to focus on clear contributions
That so many of our editors meet these thresholds reflects the impact of the communities behind our journals.
What this means going forward
This recognition underlines the fact that our strength comes from the scientific communities who choose to work with us.
For authors, partners, and readers, it confirms that:
- MDPI journals benefit from editorial guidance grounded in active, high-impact research
- Our Editorial boards include leaders who are helping shape the future direction of their fields
- MDPI continues to attract experts who value openness, efficiency, and scientific integrity
For our internal teams, it is a reminder that the work we do every day (supporting editors, refining workflows, and improving systems) directly contributes to the trust placed in MDPI by researchers worldwide.
Thank you to all our editorial teams, publishing staff, and journal relationship specialists, and to everyone who collaborates with our Editorial Boards. Achievements like this are only possible because of your ongoing hard work, dedication, and collaboration.

From our first annual MDPI UK Summit in Manchester, bringing together over 30 Chief Editors and Editorial Board Members to discuss MDPI’s mission, achievements, and collaborations in the UK.
Inside MDPI

MDPI Launches the Michele Parrinello Award for Computational Physical Science
In case you missed it, in November, we announced the launch of the Michele Parrinello Award. This new biennial international award will recognize pioneering contributions in computational physical science. The award honours Michele Parrinello, one of the most influential scientists of the past half-century in atomistic simulations and computational materials research.
This award reflects MDPI’s long-standing commitment to recognizing scientific excellence, supporting foundational research, and inspiring the next generation of scholars across disciplines.
“Be confident that what you do is meaningful”
Honouring a transformative scientific legacy
Professor Parrinello’s work has fundamentally reshaped how scientists model matter at the atomic scale. Together with Roberto Car, he introduced ab initio molecular dynamics, widely known as the Car–Parrinello method, opening new pathways in electronic structure calculations and molecular simulations. His subsequent contributions, including the Parrinello–Rahman method and metadynamics, have become core tools across physics, chemistry, materials science, and increasingly biology.

“Do not be afraid of new things. I see it many times when we discuss a new thing that young people are scared to go against the mainstream a little bit, thinking, ‘What is going to happen to me?’ and so on. Be confident that what you do is meaningful, and do not be afraid, do not listen too much to what other people have to say.”
– Professor Michele Parrinello
A global, community-led award

The award committee is chaired by Xin-Gao Gong, Professor of Physics at Fudan University and academician of the Chinese Academy of Sciences.
The Institute for Computational Physical Sciences at Fudan University will serve as the supporting institute, reinforcing the award’s international and cross-cultural foundation.
Nominations for the first edition of the Michele Parrinello Award opened on 1 November 2025, with submissions accepted until March 2026. The award will recognize scientists whose work has advanced computational physical science across physics, chemistry, and materials research – fields increasingly central to energy, sustainability, advanced manufacturing, and technological innovation.
Why this matters for MDPI
The Michele Parrinello Award is part of the MDPI Sustainability Foundation, which supports science as a driver of long-term societal progress.

Alongside other foundation-level honours, including the World Sustainability Award, the Emerging Sustainability Leader Award, and the Tu Youyou Award, this new prize builds on our role in supporting excellence across career stages and disciplines.
MDPI journals and programs continue to recognize researchers through Best Paper Awards, Young Investigator Awards, Travel Awards, Best PhD Thesis Awards, and Outstanding Reviewer Awards. Together, these initiatives reflect a simple belief: strong scientific communities are built through recognition, trust, and sustained support.
As MDPI approaches its 30th anniversary, the launch of the Michele Parrinello Award highlights our commitment not only to publishing research but also to helping shape the future of science by celebrating those who expand its boundaries.
Coming Together for Science

KEMÖ Consortium (Austria) Extends Open Access Agreement with MDPI until 2027
I’m pleased to share that MDPI has renewed its Institutional Open Access Program (IOAP) agreement with the Austrian library consortium KEMÖ, extending our partnership through 2027.
The renewed agreement now includes 23 Austrian institutions, with the Medical University of Vienna and the University of Natural Resources and Life Sciences (BOKU) joining the partnership. Participating institutions benefit from APC discounts across MDPI’s more than 495 journals, with centralized funding options further reducing the administrative burden for researchers and libraries.
“This renewal reflects shared commitment to advancing Open Access publishing in Europe”
Austria continues to be an important and engaged research community for MDPI, with 525+ Austrian Editorial Board Members, eight Editors-in-Chief, and 15 Section Editors-in-Chief contributing to our journals.
This renewal reflects long-term trust and shared commitment to advancing Open Access publishing in Europe, and improves MDPI’s collaboration with national OA infrastructures such as the Open Access Monitor Austria. Such long-term agreements show how MDPI’s growth is increasingly built on institutional trust, collaboration, and shared commitment to Open Access.
A big thank-you to the IOAP team and everyone involved in supporting this partnership.
Closing Thoughts

Celebrating the Next Generation of Scholars: MDPI’s 2024 Best PhD Thesis Awards
One of the privileges of working in scholarly publishing is supporting the beginning of new scientific journeys. We recently announced the recipients of MDPI’s 2024 Best PhD Thesis Awards, recognizing some of the most promising emerging researchers across disciplines.
These awards do more than celebrate academic excellence. They reflect something deeper about our mission: supporting the next generation of authors and the future of Open Science.
Recognition of Excellence
This year, we made awards to 55 early-career researchers across seven fields:
- Biology and Life Sciences
- Chemistry and Materials Science
- Computer Science and Mathematics
- Engineering
- Environmental and Earth Sciences
- Medicine and Pharmacology
- Interdisciplinary ‘Other’ fields
For those of you who have completed a PhD, you’ll know first-hand that behind each number is a story of perseverance, curiosity, and sustained effort. These researchers represent institutions around the world, with thesis topics spanning:
- Brain–machine interfaces and neural engineering
- Sustainable materials and next-generation batteries
- Cancer genomics, tumour microenvironments, and immunotherapy
- AI-driven image analysis, robotics, and computational models
- Climate change monitoring and environmental risk assessment
- Regenerative medicine, biomaterials, and drug development
These dissertations are early signs of the scientific directions that will shape the coming decade.
“Our mission is about building a global community of authors”
Why this is important
Every year, millions of scholars begin their research careers with limited visibility and few platforms for sharing their work. By recognizing outstanding PhD theses, we elevate authors early in their academic journeys, build MDPI’s connection to the global research community, reinforce our commitment to quality and rigor, and highlight the depth and breadth of scholarship published across our portfolio (from biology to materials science to mathematics).

A foretaste of the future
These 55 awardees represent the next generation of researchers whose work will influence science, policy, and society in the years ahead. What we support today helps shape the scientific ecosystem of tomorrow. Our mission goes beyond publishing papers. It is about building a global community of authors who will define the next era of scientific discovery.
To explore more about MDPI Awards, including current and upcoming Best PhD Thesis Awards, please click here.
Thank you to the editors, reviewers, and teams across MDPI who make these awards possible each year.
Everything we achieved this year was made possible by the collective effort of our global teams and the trust placed in us by the scholarly community. Thank you again, and here’s to the successful continuation of our collaboration in 2026!
Chief Executive Officer
MDPI AG
24 December 2025
Vaccines Travel Award—Winners Announced
We are pleased to announce the winners of the Vaccines 2026 Travel Award. The award has been granted to Ayesha Zahid, a PhD student at Griffith University, Australia, and Maja Cvetanoska, a PhD student at the Institute of Oncology Ljubljana, Slovenia.
Each winner will receive an honorarium of CHF 500 and an electronic certificate.
With so many high-quality applicants, the evaluation process and final decision were challenging. We would like to thank all the applicants for submitting their diverse and fascinating range of research topics. On behalf of the assessment committee, we congratulate the winners on their accomplishments.
Prof. Dr. Ralph A. Tripp
Editor-in-Chief of Vaccines
22 December 2025
Vaccines | Notable Papers Published in 2024 in the “Vaccines, Clinical Advancement, and Associated Immunology” Section
1. “Immunosenescence: Aging and Immune System Decline”
by Priyanka Goyani, Rafail Christodoulou and Evros Vassiliou
Vaccines 2024, 12(12), 1314; https://doi.org/10.3390/vaccines12121314
Full text available online: https://www.mdpi.com/2076-393X/12/12/1314
2. “Plaque Psoriasis Exacerbation and COVID-19 Vaccination: Assessing the Characteristics of the Flare and the Exposome Parameters”
by Emmanouil Karampinis, Myrto-Maria Papadopoulou, Kleoniki Chaidaki, Konstantina-Eirini Georgopoulou, Stavroula Magaliou, Angeliki Viktoria Roussaki Schulze, Dimitrios P. Bogdanos and Efterpi Zafiriou
Vaccines 2024, 12(2), 178; https://doi.org/10.3390/vaccines12020178
Full text available online: https://www.mdpi.com/2076-393X/12/2/178
3. “Vaccines for the Elderly and Vaccination Programs in Europe and the United States”
by Cleo Anastassopoulou, Stefanos Ferous, Snežana Medić, Nikolaos Siafakas, Fotini Boufidou, Georgia Gioula and Athanasios Tsakris
Vaccines 2024, 12(6), 566; https://doi.org/10.3390/vaccines12060566
Full text available online: https://www.mdpi.com/2076-393X/12/6/566
4. “Combating Emerging Respiratory Viruses: Lessons and Future Antiviral Strategies”
by Palaniyandi Muthukutty, Jaime MacDonald and So Young Yoo
Vaccines 2024, 12(11), 1220; https://doi.org/10.3390/vaccines12111220
Full text available online: https://www.mdpi.com/2076-393X/12/11/1220
5. “Seroprevalence for Measles, Varicella, Mumps and Rubella in the Trainee Obstetric Population: A Survey in Southern Italy”
by Brunella Perfetto, Giovanna Paduano, Elena Grimaldi, Vincenza Sansone, Giovanna Donnarumma and Gabriella Di Giuseppe
Vaccines 2024, 12(3), 335; https://doi.org/10.3390/vaccines12030335
Full text available online: https://www.mdpi.com/2076-393X/12/3/335
6. “Breakthrough Infections in SARS-CoV-2-Vaccinated Multiple Myeloma Patients Improve Cross-Protection against Omicron Variants”
by Angelika Wagner, Erika Garner-Spitzer, Claudia Auer, Pia Gattinger, Ines Zwazl, René Platzer, Maria Orola-Taus, Peter Pichler, Fabian Amman, Andreas Bergthaler et al.
Vaccines 2024, 12(5), 518; https://doi.org/10.3390/vaccines12050518
Full text available online: https://www.mdpi.com/2076-393X/12/5/518
7. “T Cell Responses during Human Immunodeficiency Virus/Mycobacterium tuberculosis Coinfection”
by José Alejandro Bohórquez, Chinnaswamy Jagannath, Huanbin Xu, Xiaolei Wang and Guohua Yi
Vaccines 2024, 12(8), 901; https://doi.org/10.3390/vaccines12080901
Full text available online: https://www.mdpi.com/2076-393X/12/8/901
8. “Durability of Adaptive Immunity in Immunocompetent and Immunocompromised Patients Across Different Respiratory Viruses: RSV, Influenza, and SARS-CoV-2”
by Achilleas Livieratos, Lars Erik Schiro, Charalambos Gogos and Karolina Akinosoglou
Vaccines 2024, 12(12), 1444; https://doi.org/10.3390/vaccines12121444
Full text available online: https://www.mdpi.com/2076-393X/12/12/1444
9. “Immunity to Sexually Transmitted Bacterial Infections of the Female Genital Tract: Toward Effective Vaccines”
by Kacy S. Yount and Toni Darville
Vaccines 2024, 12(8), 863; https://doi.org/10.3390/vaccines12080863
Full text available online: https://www.mdpi.com/2076-393X/12/8/863
10. “Comparative Evaluation of Recombinant and Acellular Pertussis Vaccines in a Murine Model”
by Kyu-Ri Kang, Ji-Ahn Kim, Gyu-Won Cho, Han-Ul Kang, Hyun-Mi Kang, Jin-Han Kang, Baik-Lin Seong and Soo-Young Lee
Vaccines 2024, 12(1), 108; https://doi.org/10.3390/vaccines12010108
Full text available online: https://www.mdpi.com/2076-393X/12/1/108
19 December 2025
Meet Us at the ESCMID Global 2026, 17–21 April 2026, Munich, Germany
MDPI will be attending the ESCMID Global 2026, which will be held from 17 to 21 April 2026, in Munich, Germany.
ESCMID Global 2026 stands as the largest international conference in the fields of clinical microbiology and infectious diseases, dedicated to connecting scientists, doctors, veterinarians and other healthcare professionals worldwide. Centered on combating antimicrobial resistance (AMR), this annual congress serves as a pivotal platform for driving innovation and collaboration in the sector.
The conference covers a wide spectrum of key areas, including scientific research, infection management, and innovations in therapeutics, diagnostics and vaccines. Attendees will have the opportunity to access the latest scientific breakthroughs, transformative treatments and rapid diagnostic technologies, making it an essential event for those looking to connect, learn and lead the future of infectious disease control.
The following MDPI journals will be represented:
- Antibiotics;
- JCM;
- Microorganisms;
- COVID;
- Hygiene;
- JMP;
- Clinics and Practice;
- Diseases;
- Immuno;
- Medical Sciences;
- Vaccines.
If you plan on attending this conference, please feel free to stop by our booth at #G46 and have a conversation with us. Our delegates look forward to meeting you in person and answering any questions that you may have. For more information about the conference, please visit the following link: https://www.escmid.org/congress-events/escmid-global/munich-2026/.
17 December 2025
Vaccines | Notable Papers Published in 2024 in the “Vaccination Against Cancer and Chronic Diseases” Section
1. “New Emerging Targets in Cancer Immunotherapy: The Role of B7-H3”
by Ioannis-Alexios Koumprentziotis, Charalampos Theocharopoulos, Dimitra Foteinou, Erasmia Angeli, Amalia Anastasopoulou, Helen Gogas and Dimitrios C. Ziogas
Vaccines 2024, 12(1), 54; https://doi.org/10.3390/vaccines12010054
Full text available online: https://www.mdpi.com/2076-393X/12/1/54
2. “Centrosomal Protein 55 (CEP55) Drives Immune Exclusion and Resistance to Immune Checkpoint Inhibitors in Colorectal Cancer”
by Dechen Wangmo, Travis J. Gates, Xianda Zhao, Ruping Sun and Subbaya Subramanian
Vaccines 2024, 12(1), 63; https://doi.org/10.3390/vaccines12010063
Full text available online: https://www.mdpi.com/2076-393X/12/1/63
3. “Exosome-like Systems: From Therapies to Vaccination for Cancer Treatment and Prevention—Exploring the State of the Art”
by Hamid Heydari Sheikhhossein, Francesca Iommelli, Natalia Di Pietro, Maria Cristina Curia, Adriano Piattelli, Rosanna Palumbo, Giovanni N. Roviello and Viviana De Rosa
Vaccines 2024, 12(5), 519; https://doi.org/10.3390/vaccines12050519
Full text available online: https://www.mdpi.com/2076-393X/12/5/519
4. “Dendritic Cells as a Therapeutic Strategy in Acute Myeloid Leukemia: Vaccines”
by Francisca Palomares, Alejandra Pina, Hala Dakhaoui, Camila Leiva-Castro, Ana M. Munera-Rodriguez, Marta Cejudo-Guillen, Beatriz Granados, Gonzalo Alba, Consuelo Santa-Maria, Francisco Sobrino et al.
Vaccines 2024, 12(2), 165; https://doi.org/10.3390/vaccines12020165
Full text available online: https://www.mdpi.com/2076-393X/12/2/165
5. “Synergistic Effects of Metal–Organic Nanoplatform and Guanine Quadruplex-Based CpG Oligodeoxynucleotides in Therapeutic Cancer Vaccines with Different Tumor Antigens”
by Xia Li, Mitsuhiro Ebara, Naoto Shirahata, Tomohiko Yamazaki and Nobutaka Hanagata
Vaccines 2024, 12(6), 649; https://doi.org/10.3390/vaccines12060649
Full text available online: https://www.mdpi.com/2076-393X/12/6/649
6. “Characterization of the Anti-Viral and Vaccine-Specific CD8+ T Cell Composition upon Treatment with the Cancer Vaccine VSV-GP”
by Tamara Hofer, Lisa Pipperger, Sarah Danklmaier, Krishna Das and Guido Wollmann
Vaccines 2024, 12(8), 867; https://doi.org/10.3390/vaccines12080867
Full text available online: https://www.mdpi.com/2076-393X/12/8/867
7. “Oncolytic Adenovirus Armed with a Novel Agonist of the CD137 Immune Checkpoint Stimulator Suppresses Tumor Growth”
by Martin R. Ramos-Gonzalez, Mohammad Tarique, Lalit Batra, Feyza Arguc, Rodolfo Garza-Morales, Haval Shirwan, Esma S. Yolcu and Jorge G. Gomez-Gutierrez
Vaccines 2024, 12(3), 340; https://doi.org/10.3390/vaccines12030340
Full text available online: https://www.mdpi.com/2076-393X/12/3/340
8. “TLR7 Agonist-Loaded Gadolinium Oxide Nanotubes Promote Anti-Tumor Immunity by Activation of Innate and Adaptive Immune Responses”
by Xiupeng Wang, Motohiro Hirose and Xia Li
Vaccines 2024, 12(4), 373; https://doi.org/10.3390/vaccines12040373
Full text available online: https://www.mdpi.com/2076-393X/12/4/373
9. “Anti-Tumor Immunity to Patient-Derived Breast Cancer Cells by Vaccination with Interferon-Alpha-Conditioned Dendritic Cells (IFN-DC)”
by Caterina Lapenta, Stefano Maria Santini, Celeste Antonacci, Simona Donati, Serena Cecchetti, Patrizia Frittelli, Piera Catalano, Francesca Urbani, Iole Macchia, Massimo Spada et al.
Vaccines 2024, 12(9), 1058; https://doi.org/10.3390/vaccines12091058
Full text available online: https://www.mdpi.com/2076-393X/12/9/1058
10. “GSK-3β in Dendritic Cells Exerts Opposite Functions in Regulating Cross-Priming and Memory CD8 T Cell Responses Independent of β-Catenin”
by Chunmei Fu, Jie Wang, Tianle Ma, Congcong Yin, Li Zhou, Björn E. Clausen, Qing-Sheng Mi and Aimin Jiang
Vaccines 2024, 12(9), 1037; https://doi.org/10.3390/vaccines12091037
Full text available online: https://www.mdpi.com/2076-393X/12/9/1037
11 December 2025
Article Layout and Template Revised for Future Volumes
We are pleased to announce updates to our article template, aimed at improving the readability and visual appeal of our publications. The following updates will be applied to articles published in volumes in 2026, starting from 19 December 2025.
Left information bar:
- Updated the logo and URL for “Check for updates”;
- Removed the “Citation” section (Note: Citation details remain accessible via “Cite” in the online article version);
- Changed the link in “Copyright” to a hyperlink format.
Footer:
- Added a DOI link at the bottom-right corner of each page.
The updated template is now available for download from the Instructions for Authors page of each journal.
We hope that the new version of the template will provide users with better experience and make the process more convenient.
For any questions or suggestions, please contact our production team at production@mdpi.com.
1 December 2025
World AIDS Day, 1 December 2025
1 December is World AIDS Day, the day is an opportunity for public and private partners to spread awareness about the status of the pandemic and encourage progress in HIV/AIDS prevention, treatment, and care around the world. It has become one of the most widely recognized international health days.
In recognition of this day, we recommend the following related articles, Special Issues, and journals spanning multidisciplinary fields, including clinical medicine and biology. We believe that sharing such research can raise the public’s awareness and understanding of AIDS. The aim is to strengthen scientific cooperation in response to increased awareness about HIV/AIDS and to demonstrate international solidarity in the face of the pandemic.

| Biology & Life Science | Medicine & Pharmacology | Social Science, Art and Humanities |
|
||

“Progress and Challenges in HIV-1 Vaccine Research: A Comprehensive Overview”
by Alex C. Boomgarden and Chitra Upadhyay
Vaccines 2025, 13(2), 148; https://doi.org/10.3390/vaccines13020148
“Drug-Drug Interactions Between HIV Antivirals and Concomitant Drugs in HIV Patients: What We Know and What We Need to Know”
by Emanuela De Bellis, Danilo Donnarumma, Adele Zarrella, Salvatore Maria Mazzeo, Annarita Pagano, Valentina Manzo, Ines Mazza, Francesco Sabbatino, Graziamaria Corbi, Pasquale Pagliano et al.
Pharmaceutics 2025, 17(1), 31; https://doi.org/10.3390/pharmaceutics17010031
“High Prevalence of High-Risk HPV Among People with and Without HIV: Insights into Risk Factors for Tailored Screening Approaches”
by Elena Bruzzesi, Federica Gandini, Sara Diotallevi, Riccardo Lolatto, Massimo Cernuschi, Caterina Candela, Angelo Roberto Raccagni, Flavia Passini, Andrea Marco Tamburini, Roberto Burioni et al.
Microorganisms 2024, 12(12), 2571; https://doi.org/10.3390/microorganisms12122571
“Association Between Left Ventricular Diastolic Dysfunction, Systemic Inflammation, and Gastrointestinal Symptoms in HIV-Positive Patients on Antiretroviral Therapy”
by Madalina-Ianca Suba, Bogdan Hogea, Ahmed Abu-Awwad, Voichita Elena Lazureanu, Ovidiu Rosca, Daniela Gurgus, Sorina Maria Denisa Laitin and Alina Abu-Awwad
Diseases 2024, 12(12), 313; https://doi.org/10.3390/diseases12120313
“NSC95397 Is a Novel HIV-1 Latency-Reversing Agent”
by Randilea Nichols Doyle, Vivian Yang, Yetunde I. Kayode, Robert Damoiseaux, Harry E. Taylor and Oliver I. Fregoso
Viruses 2024, 16(11), 1783; https://doi.org/10.3390/v16111783
“HIV Self-Testing: A Discussion on the Benefits, Limitations, and Implications for Public Health with a Focus on Poland”
by Aleksandra Kozieł, Igor Domański, Aleksandra Szymczak, Tomasz Dudzik, Brygida Knysz and Bartosz Szetela
Diagnostics 2024, 14(22), 2475; https://doi.org/10.3390/diagnostics14222475
“Tumor Initiation and Progression in People Living on Antiretroviral Therapies”
by Seun E. Olufemi, Daniel A. Adediran, Temitope Sobodu, Isaac O. Adejumo, Olumide F. Ajani and Elijah K. Oladipo
Biologics 2024, 4(4), 390-406; https://doi.org/10.3390/biologics4040024
“J3ExoA: A Novel Anti-HIV Immunotoxin Fusion of Anti-Gp120 J3VHH and PE38 Fragment of Pseudomonas Exotoxin A”
by Seth H. Pincus, Kun Luo, Tami Peters, James T. Gordy, Frances M. Cole, Grant Klug, Kelli Ober, Tamera K. Marcotte and Richard B. Markham
Pharmaceuticals 2025, 18(9), 1305; https://doi.org/10.3390/ph18091305
“A Memo on Factors Associated with Perception of Stigma Attached to PrEP: Evidence from the Keeping It LITE Study”
by Shahin Davoudpour, Gregory L. Phillips II, Pedro A. Serrano, Audrey L. French and Sybil G. Hosek
Sexes 2024, 5(3), 300-316; https://doi.org/10.3390/sexes5030023
“Effects of E-Cigarettes on the Lung and Systemic Metabolome in People with HIV”
by Aline Zaparte, Courtney J. Christopher, Connie Arnold, Lauren Richey, Adairre Castille, Kyle Mistretta, Christopher M. Taylor, Huiyi Lin, Steve Nelson, John P. Kirwan, John W. Apolzan, Shawn R. Campagna and David A. Welsh
Metabolites 2024, 14(8), 434; https://doi.org/10.3390/metabo14080434
“Bone Tissue Changes in Individuals Living with HIV/AIDS: The Importance of a Hierarchical Approach in Investigating Bone Fragility”
by Jelena Jadzic, Gordana Dragovic, Relja Lukic, Bozana Obradovic and Marija Djuric
J. Pers. Med. 2024, 14(8), 791; https://doi.org/10.3390/jpm14080791
“Advanced Therapies for Human Immunodeficiency Virus”
by Daniel Josef Lindegger
Med. Sci. 2024, 12(3), 33; https://doi.org/10.3390/medsci12030033
“Antiretroviral Therapy Switch in HIV-Infected Adults from a Regional HIV/AIDS Center in NE Romania”
by Isabela Ioana Loghin, Șerban Alin Rusu, Andrei Vâţă, Mihaela Cobaschi, Ion Cecan, Carmen Manciuc and Carmen Mihaela Dorobăţ
Medicina 2024, 60(6), 854; https://doi.org/10.3390/medicina60060854
“Alterations in the Gut Microbiome Composition of People Living with HIV in the Asia–Pacific Region: A Systematic Review”
by Paul Benedic U. Salvador, Patrick Josemaria d. R. Altavas, Mark Angelo S. del Rosario, Eric David B. Ornos and Leslie Michelle M. Dalmacio
Clin. Pract. 2024, 14(3), 846-861; https://doi.org/10.3390/clinpract14030066
“Systematic Review: HIV, Aging, and Housing—A North American Perspective, 2012–2023”
by Arthur S. Chaminuka, Gayle Prybutok, Victor R. Prybutok and William D. Senn
Healthcare 2024, 12(10), 992; https://doi.org/10.3390/healthcare12100992
“The Role of MicroRNAs in HIV Infection”
by Nicolas Morando, Mara Cecilia Rosenzvit, Maria A. Pando and Jens Allmer
Genes 2024, 15(5), 574; https://doi.org/10.3390/genes15050574

|
“HIV-TB Co-Infection and Pediatric Pathogen Dynamics” |
“HIV Expression in Diverse Cell Types: Mechanisms, Regulation, and Pathogenesis” |
![]() |
![]() |
|
“Research on HIV/AIDS Vaccine” |
“Gene and Cell Therapy: New Findings from Medical Research and Treatment” |
![]() |
![]() |
|
“Emerging Knowledge on Human Immunodeficiency Virus” |
“Nutrition Intervention in HIV Patients” |
![]() |
![]() |
















